Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Scottish Medicines Consortium Accepts Kite CAR T-Cell Therapy for Earlier Use to Treat Aggressive Blood Cancers - First SMC acceptance of any CAR T-cell therapy for lymphoma patients in the ...

SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today ...

Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.

A replay will also be available following the live event. TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with ...

Reneo Pharmaceuticals Inc (RPHM) is expected to report for 3Q. Renovaro Inc (RENB) is expected to report for 1Q. SELLAS Life Sciences Group Inc (SLS) is expected to report $-0.13 for 3Q. Siebert ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...